Brief: Kiora Pharmaceuticals Receives Ind Approval To Initiate Abacus-2, A Phase 2 Clinical Trial Of Kio-301 For Treatment Of Retinitis Pigmentosa
29/10/2024 11:26
Oct 29 (Reuters) -
* KIORA PHARMACEUTICALS: RECEIVES IND APPROVAL TO INITIATE
ABACUS-2, A PHASE 2 CLINICAL TRIAL OF KIO-301 FOR TREATMENT OF
RETINITIS PIGMENTOSA
* KIORA PHARMACEUTICALS: DOSING OF FIRST PATIENT WITH
KIO-301 IS
EXPECTED TO BEGIN NEXT YEAR
Source text: ID:n0001372514-24-000117
Further company coverage: KPRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kiora Pharmaceuticals
See all newsKiora Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Kiora Pharmaceuticals, Inc. expected to post a loss of 62 cents a share - Earnings Preview
Brief: Kiora Pharmaceuticals Inc - Enters Securities Purchase Agreement On April 3, 2026 - SEC Filing
Kiora Pharmaceuticals posts 2025 net loss as expenses rise
Brief: Kiora Pharmaceuticals Files For Mixed Shelf Offering Of Up To $100 Million- SEC Filing